The INFUSE-Morphine IIB Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneous Morphine in Healthy Volunteers

Abstract Morphine is usually given intravenously (IV) for the treatment of moderate-to-severe pain, but subcutaneous (SC) administration is a viable alternative for parenteral delivery. The pharmacokinetics of SC morphine may be enhanced by coadministration with a hyaluronidase product. In this Phas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of pain and symptom management 2009-11, Vol.38 (5), p.673-682
Hauptverfasser:	Thomas, Jay R., MD, PhD, Yocum, Richard C., MD, Haller, Michael F., PhD, Flament, Jocelyne, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Absorption Adult Aged Analgesics, Opioid - administration & dosage Analgesics, Opioid - pharmacokinetics Anesthesia & Perioperative Care Biological and medical sciences Concentration Cross-Over Studies difficult venous access Dosage Double-Blind Method Female hospice Humans Hyaluronoglucosaminidase - adverse effects Hyaluronoglucosaminidase - pharmacology Injections, Subcutaneous interstitial Male Medical sciences Middle Aged Morphine Morphine - administration & dosage Morphine - pharmacokinetics pain Pain Medicine palliative care parenteral pharmacokinetics Pharmacology. Drug treatments Recombinant human hyaluronidase Recombinant Proteins - adverse effects Recombinant Proteins - pharmacology Safety subcutaneous Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!